FDA notice on Zepbound®/Mounjaro® shortage: On October 2, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, had ended. (Read more) Schedule a visit with an Ivim … Read more
FDA notice on Zepbound®/Mounjaro® shortage: On October 2, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, had ended. (Read more) Schedule a visit with an Ivim … Read more
FDA notice on Zepbound®/Mounjaro® shortage: On October 2, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, had ended. (Read more) Schedule a visit with an Ivim … Read more
Introduction to Metabolic Weight Loss Metabolic weight loss delves deeper than the surface-level concept of “calories in versus calories out” that’s often associated with traditional weight loss methods. Instead, it focuses on optimizing the body’s metabolic rate—the … Read more
Introduction In the dynamic landscape of modern medicine, the practice of pharmaceutical compounding has found renewed relevance. This intricate process of tailoring medications isn’t just about mixing ingredients; it represents a holistic approach, aiming to customize treatments … Read more
Introduction to Compounded Semaglutide Compounded semaglutide, initially developed and introduced for the management of type 2 diabetes, has garnered significant attention in the medical community for its impressive efficacy. As a glucagon-like peptide-1 (GLP-1) receptor agonist, compounded semaglutide works … Read more
FDA notice on Zepbound®/Mounjaro® shortage: On October 2, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, had ended. (Read more) Schedule a visit with an Ivim … Read more
Liraglutide (the active ingredient in Saxenda®)[1] and semaglutide (the active ingredient in Wegovy® and Ozempic®)[2] are both medications that belong to the same class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. Saxenda® (liraglutide), Wegovy® (semaglutide) is … Read more
Obesity is a growing health concern worldwide, and it is associated with an increased risk of developing several chronic diseases, including type 2 diabetes, heart disease, and certain types of cancer. While diet and exercise are the … Read more
